About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Pipeline
Publications and Presentations
News
News
Events
Careers
Investors
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Fungal Infections
Invasive Candidiasis
Invasive Aspergillosis
MARIO
Community Infections
Vulvovaginal Candidiasis
Recurrent VVC
Pipeline
Publications and Presentations
Our Science
Publications and Presentations
Date
Title
×
Announcement
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
View Press Release
SCYNEXIS Announces $40 million Private Placement
View Press Release